All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Inotek Pharmaceuticals Corp., of Lexington, Mass., said active recruitment for Matrx-1, the first pivotal phase III trial of trabodenoson for the treatment of glaucoma, is complete.